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ABSTRACT 
 
Oral delivery of drugs is by far the most preferable route of drug delivery.  This route has high patient acceptability, 
primarily due to ease of administration. Effective oral drug delivery depend upon the factors such as gastric 
emptying process, gastrointestinal transit time of the dosage form ,drug release from the dosage form, and site of 
absorption of drug. In the recent years, scientific and technological advancement have been made in the research and 
development of gastroretentive drug delivery system. Henceforth a wide spectrum of dosage form have been 
developed for the drugs which have narrow absorption window, unstable at intestinal pH , soluble in acidic pH and 
have site of action specific to stomach.The purpose of writing this review was to investigate, compile and present 
the recent as well as past literatures in more concise way with special focus on approaches which are currently 
utilized in the prolongation of gastric residence time. These includes floating system, swelling and expanding 
system, bio/mucoadhesive system, high density system and other delayed gastric emptying devices. The present 
review addresses briefly about the classification, formulation consideration for GRDDS, factors controlling gastric 
retention, merits , demerits and applications of gastroretentive drug delivery systems. 
Key words: gastroretentive drug delivery system ; floating system; swelling; expanding system; bio/mucoadhesive 
system; high density system 
INTRODUCTION 
 
Despite of considerable advancements in the drug 
delivery, oral delivery of drugs is the most preferred 
route because of its ease of administration[1] and low 
cost of  therapy and high level of patient compliance. 
Oral controlled release drug delivery system have 
drawn considerable attention as these systems provide 
drug release at a predetermined, predictable and 
controlled rate. However some drugs show poor 
bioavailability because of incomplete absorption or 
degradation in the git [2].Therefore to overcome such 
problems gastroretentive drug delivery systems are 
designed to prolong the gastric retention time of the 
drugs  which are: 
❖ Locally active in the stomach. 
❖ Unstable in the intestinal environment. 
❖ Have narrow absorption window in the git. 
❖ Have low solubility at the high pH regions.[3] 
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Various approaches have been proposed to increase the 
gastric residence of the drug delivery that includes 
floating drug delivery system (FDDS), mucoadhesion 
or bioadhesion system, high density system, expansion 
system, magnetic system, superporous huydrogel, raft 
forming system and floating ion exchange resins.[4] 
 
Potential candidates for gastroretentive drug 
delivery system 
1. Drugs that are primarily absorbed in the 
stomach eg Amoxicillin. 
2. Drugs that are poorly soluble in alkaline pH eg 
Furosemide , Diazepam. 
3. Drugs that have narrow absorption window eg 
Levodopa, Methotrexate. 
4. Drugs that degrade in the colon eg. Ranitidine , 
Metformin HCL. 
5. Drugs that disturb normal colonic microbes eg 
Antibiotics against Helicobacter pylori. 
6. Drugs rapidly absorbed from the gi tract eg 
Tetracycline. 
7. Drugs acting locally in the stomach[5]. 
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Advantages of gastroretentive drug delivery 
system 
1. It increases patient compliance by 
reducing dosing frequency 
2. Buoyancy increases gastric residence 
time 
3. Better therapeutic effect of short half life 
drugs 
4. Site specific drug delivery to stomach can 
be achieved 
5. In this drug is released in a controlled 
manner  
6. Gastric irritation can be avoided by 
designing sustained release. 
7. No risk of dose dumping by making 
single unit floating unit such as 
microspheres releases drug uniformly.[6] 
 
Limitations of gastroretentive drug delivery system 
1. Aspirin and NSAID’S can cause gastric 
lesions and slow release of such drug in 
the stomach is unwanted. 
2. Drugs such as isosorbide dinitrate which 
are equally absorbed throughout the GIT 
will not be benefit from incorporation into 
a gastric retention system. 
3. Bioadhesion in the acidic environment 
and high turnover of mucus may raise 
questions about the effectiveness of the 
technique 
4. Physical integrity of the system is very 
important and primary requirement for the 
success of the system. 
5. High variability in gastric emptying time 
due to variations in emptying process , 
unpredictable bioavailbility.[6][7] 
Anatomy of the stomach 
The gastro intestinal tract can be divided into three main regions 
• Stomach 
• Small intestine- duodenum, jejunum, and ileum 
• Large intestine 
 
 
Figure 1: Shows parts of Stomach 
The git is a muscular tube of about 9m which extends 
from mouth to anus. Its function is to take nutrients and 
eliminate out waste product by physiological processes 
such as digestion, absorption, secretion, motility and 
excretion. The stomach has three muscle layer called 
oblique muscle and it is situated in the proximal part of 
the stomach, branching over the fundus and higher 
regions of the gastric body. The stomach is divided  
into fundus, body and pylorus[8]. The stomach is a J 
shaped organ located in the upper left hand portion of 
the abdomen. The main function of the stomach is to 
store the food temporarily , grind it and releases slowly 
in to the duodenum. 
Physiology of the stomach 
The stomach is an expanded section of the digestive 
tube between the oesophagus and small intestine.  In 
the empty state the stomach is contracted and its 
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mucosa and sub mucosa are thrown upinto folds called 
rugae. There are 4 major types of secretory epithelial 
cells that covers the stomach and extends into gastric 
pits and glands. 
1. mucous cells- secrete alkaline mucus 
2. parietal cells – secrete HCL 
3. chief cells- secrete pepsin 
4. G cells- secrete hormone gastrin[9]. 
  
 
Gastric motility and gastric empty rate 
 
Two distinct patterns of gastrointestinal motility and 
secretion exist to the fasted and fed state. The 
bioavailbility of the orally adminsterd drug depend 
upon the state of feeding. In the fasted state , it is 
characterized by an interdigestive series of electric 
event  called inter digestive myoelectric cycle or 
migrating motar complex. 
It is divided  into 4 phases[10] 
• phase I (basal phase) it lasts from 40-60 min 
with rare contractions 
• phase II (preburust phase) last from 40-60min 
with intermittent potential and contractions. 
• Phase III (burst phase) last for 4-6 min. in this 
intense and regular contraction occur for short 
periods. Due to these contractions the 
undigestive food is swept from stomach to 
intestine. These are known as house keeper 
waves. 
• Phase IV it lasts for 0-5 min and occurs between 
phases III and I for two consecutive cycles. 
 
After the ingestion of the mixed meal the pattern of 
contraction changes from fed to that of fasted state, this 
is known as digestive motility pattern, these 
contractions reduces the size of the food particles to 
less than 1mm after that it is propelled to the pylorus in 
the suspension form. During fed state the onset of 
MMC is delayed which result in slow down of gastric 
emptying rate.[11] 
                                                                  
 
                                                     
Figure 2 :Shows general  Gastrointestinal tract 
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 Figure 3: Shows Physiology of stomach 
 
Factors affecting gastric retention 
 
Density: The density of the dosage form should be less 
than that of the gastric contents (1.004g/ml) 
 
Size: Dosage form having diameter of more than 
7.5mm have more gastric residence time than that of 
9.9mm diameter dosage form. 
 
Shape of the dosage form: The tetra hedron resided in 
the stomach for longer period than other devices of 
similar size. 
Single or multiple unit formulation- multiple unit 
formulation show a more predictable release profile 
and insignificant impairing of the performance due to 
failure of the units. , allow co-adminstration of units 
with different release profile or containing 
incompatible substances and permit larger margin of 
safety against dosage form failure compared with 
single unit dosage form[12]. 
 
Fed or unfed state: Under fasting conditions, the gi 
motility is characterized by periods of strong motar 
activity that occurs every 1.5-2 hrs. the MMC sweeps 
undigested material from the stomach and if the timing 
of the formulation coincides with that of MMC ,the 
GRT of the unit can be very short, however in fast state 
MMC is delayed and GRT  is longer. 
 
Nature of meal:Feeding of indigestible polymers or 
fatty acids can change the motility pattern of the 
stomach to a fed state,thus decreasing gastric emptying 
rate and prolonging drug release.[13] 
 
Caloric content:GRT can be increased by 4-10 with a 
meal that is high in protein and fat [14]. 
 
Frequency of feed: The GRT can be increase over 400 
min when successive meals given are compared with 
the single meal due to low frequency of MMC. 
  
Gender: Mean ambulatory GRT in male (3.4hrs) is 
less compared with the age and race matched female 
counterparts(4.6hrs) regardless of height, weight and 
body surface. 
 
Age:People with age more than 70 have a significant 
longer GRT[15]. 
 
Concomitant drug administration- anticholinergics 
like atropine and propetheline, opiates like codeine can 
prolong GRT[2, 15]. 
 
 
Gastroretentive dosage form 
 
Gastroretentive dosage forms are the systems that can 
stay in the gastric region for several hours and thus, 
prolong the gastric residence time of the drugs. After 
oral administration, such a dosage form is retained in 
the stomach and releases the drug  in a controlled and 
sustained manner so that the drug can be supplied 
continuously in the upper GIT. This prolonged gastric 
retention improves bioavailability, decreases drug 
wastage, and improves solubility of drugs that are less 
soluble in a high pH environment.[16]    
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                                           Figure 4: Shows Cycle for Gastroretentive dosage forms 
Classification of GRDF 
• High density system 
• Floating system 
• Expandable system 
• Superporous hydrogels 
• Mucoadhesive bioadhesive system 
• Magnetic system 
High density system 
This approach involves formulation of dosage forms 
with density that must must exceed density of normal 
stomach content(1.004g/ml). these formulations are 
prepared by coating drug on a heavy core  or mixed 
with heavy inert material such as iron powder, zinc 
oxide, titanium dioxide, barium sulphate. The resultant 
pellets can be coated with diffusion controlled 
membrane [17]. 
These systems have some drawbacks like they are 
technically difficult to manufacture with a large 
amount of drug because the dry material of which it is 
made interacts within the gastric fluid to release its 
drug contents. One other problem is that no such 
system is available in the market. 
Floating or low density system 
By virtue of their low densities, FDDS remain afloat 
above the gastric contents for prolonged periods of 
time and provide continuous release of the drug. These 
systems in particular have been extensively studied 
because they do not adversely affect the motility of the 
GIT. Their dominance over the other types of GRRDS 
is also evident from the large number of floating 
dosage forms being commercialized and marketed 
world-wide.[18] 
 
                   Figure 5: Shows schematic localization of floating dosage forms in stomach 
List of drugs explored for various floating system 
Microspheres tablets/ pills: Aspirin, Griseofulvin, 
Acetyl salicyclic acid, Ibuprofen, Ampicillin, 
Captopril, Sotalol, Isosrbide dinitrate, Terfanadine. 
Films: Cinnarizine,Peritanide, Quinidine,Prednisolone, 
P-aminobenzoic acid, Prednisolone. 
Granules: Diclofenac sodium, Cinnarizine, 
Indomethacin,Fluorouracil,Diltiazem,Isosorbidedinitrat
e, Isosorbide mononitrate. 
Powders: Riboflavin, Sotalol, Theophylline 
Capsules: Verapamil HCL, Diazepam, Misoprostol, 
Furosemide, L –dopa,Nicardipine[19]. 
Classification of floating system 
 
• Non effervescent systems 
• Effervescent system 
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Effervescent FDDS 
 
 
 
Figure 6: Shows working of effervescent FDDS 
 
Volatile liquid containing system 
  
The GRT of  a drug delivery system can be sustained 
by incorporating an inflatable chamber, which contains 
a liquid e.g. ether, cyclopentane, that gasifies at body 
temperature to cause the inflatation of the chamber in 
the stomach. The device may also consist of a 
bioerodible plug made up of Poly vinyl alcohol, 
Polyethylene etc. that gradually dissolves causing the 
inflatable chamber to release gas and collapse after a 
predetermined time to permit the spontaneous ejection 
of the inflatable systems from the stomach[20]. 
 
 
 
 
                                              Figure 7: Inflatable Gastrointestinal Delivery System 
 
Gas-generating Systems: These buoyant delivery 
systems utilize effervescent reactions between 
carbonate/bicarbonate salts and citric/tartaric acid to 
liberate CO2, which gets entrapped in the jellified 
hydrocolloid layer of the systems thus decreasing its 
specific gravity and making it to float over gastric 
content. 
 
 Non-Effervescent FDDS: The Non-effervescent 
FDDS is based on mechanism of swelling of polymer 
or bioadhesion to mucosal layer in GI tract. The most 
commonly used excipients in non effervescent FDDS 
are gel forming or highly swellable cellulose type 
hydrocolloids, hydrophilic gums, polysaccharides and 
matrix forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as 
bioadhesive polymers such as Chitosan.[21]  
 
Mucoadhesive systems  
mucoadhesive drug delivery systems contain, a 
mucoadhesive polymers that adheres to the gastric 
mucosal surface and prolong its gastric retention in the 
git. The capability to adhere to the mucus gel layer 
makes mucoadhesive polymers very useful exicipients 
in the GRRDS. These polymers can be natural such as 
sodium alginate, gelatin , guar gum etc semisynthetic 
polymers such as HPMC, carbopol,sodium carboxy 
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methyl cellulose[22].The adhesion of polymers with 
mucous membrane may be mediated by hydration, 
bonding,or receptor mediated. In hydration mediated 
adhesion , the hydrophilic polymer become sticky and 
mucoadhesive upon hydration. Bonding mediated 
involves mechanical or chemical bonding.chemical 
bonds may involve ionic or covalent bonds or vander 
waal forces between the polymer molecule and the 
mucous membrane. Receptor mediated adhesion takes 
place between certain polymers and specific receptors 
expressed on gastric cells. The polymers can be 
cationic or anionic or neutral[23]. 
Swelling system 
These are the dosage forms , which after swallowing 
swells to such an extent that their exit from the pylorus 
is prevented, as a result the dosage form is retained in 
the stomach for a prolonged period of time. These 
systems are called as plug –type system as they have 
the tendency to remain lodged at the pyloric sphincter. 
The formulations are designed for gastric retention and 
controlled delivery of drugs in the gastric cavity, such 
formulations remain in the gastric cavities for several 
hours even in the fed state. Controlled and sustained 
release may be achieved by selection of proper 
molecular weight polymer, and swelling of the 
polymers retard the release [24]. On coming in contact 
with gastric fluid the polymer imbibes water and 
swells. The extensive swelling of these polymers is due 
to the presence of physical chemical cross links in the 
hydrophilic polymer network. These cross links 
prevents the dissolution of the polymer and hence 
maintain the physical integrity of the dosage form. An 
optimum cross-linking, which maintains a balance 
between the swelling and the dissolution, should be 
maintained. Agyilirah developed a polymeric coating 
system that formed an outer membrane on the 
conventional tablets. In the dissolution media the 
membrane detached from the core and sweeled to form 
a balloon that kept the unit floating . the size of the 
units increased by three to six folds, thus the floating 
ability as well as the increased dimension offered the 
system gastroretentive property[25].   
Superporous hydrogels  
Superporous hydrogels are swellable systems that 
differ from conventional types. Absorption of water by 
conventional hydrogel is very slow process and several 
hours may be required to reach the equilibrium 
states[26] during which the premature evacuation of 
the dosage form may occur. Superporous hydrogel 
have a pore size >100µm which swell to equilibrium 
size within a minutes, due to rapid intake of waterby 
capillary wetting through inter connected open pores. 
They swell to a larger size and have sufficient 
mechanical strength to withstand the pressure by 
gastric contraction. This is achieved by co- formulation 
of a hydrophilic particulate material, Ac-Di-Sol[27]. 
Magnetic system 
This system is based on the simple idea that the dosage 
form  contains a small internal magnet, and a magnet 
placed on the abdomen over the position of the 
stomach. Using a extracorporeal magnet , gastric 
residence time of the dosage form can be enhanced for 
a prolonged period of time[28]. 
Invitro method of evaluation 
Fourier transform infrared analysis 
Fourier transform infrared spectroscopy is mostly used 
to identify organic, polymeric, functional group, and 
some inorganic materials as well. FT-IR measurement 
of pure drug, polymer and drug loaded formulations are 
obtained by using this technique[29]. The pellets are 
prepared on kbr press under hydraulic pressure of 
150kg/cm2 and the spectra are scanned over the wave 
number range of 3600-400cm-1 at ambient 
temperature[30]. 
Differential scanning calorimetry 
DSC are performed to characterize water of hydration 
of pharmaceuticals. Thermo grams of formulated 
preparations are obtained using DSC instrument 
equipped with an inter cooler zinc standards are used to 
calibrate the DSC temperature  and enthalpy scale[31]. 
The sample preparations are sealed in aluminium pan 
and heated at a constant rate of 10ºC/min over a temp 
range 25ºC-65ºC[32]. 
Particle size analysis and surface characterization 
(for floating microspheres and beads) 
The particle size and size distribution of beads or 
microspheres are determined in the dry state using 
optical microscopy method. The external and cross 
sectional morphology is done by scanning electron 
microscope[33-34]. 
Floatation studies 
The invitro buoyancy is characterized by floating lag 
time and total floating time[35]. The FLT and TFT  are 
measured by placing the tablets in a 250 ml beaker 
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containing 200ml of 0.1N HCL. The time required by 
the to rise to the surface and float is known as floating 
lag time and the time period upto which the tablet 
remained buoyant is called toatal floating time[36][37]. 
Swelling studies 
Swelling of tablet excipients particles involves the 
absorption of a liquid resulting in increase in weight 
and volume . liquid uptake by the particles may be due 
to saturation of the capillary spaces within the particles 
or hydration of macromolecules[36]. The liquid enters 
the particles through pores and bind to large molecules, 
breaking the hydrogen bond and resulting in the 
swelling of particles. Tablet is weighed and placed in a 
beaker containing 200 ml of 0.1N HCL. after each 
interval the tablet is removed from the beaker, soaked 
by using filter paper and weighed again[38]. 
Swelling index (SI) = (Wt-WO)/WO × 100 
Wt –  weight of the tablet at time t 
WO – initial weight of the tablet 
Determination of drug content 
Percentage drug content provides how much amount of 
drug is present in the formulation. It should not exceed 
the limit acquired by the monograph.drug content is 
determined by using HPLC, HPTLC methods,  
microtitrimetric methods, and also by using 
spectroscopy techniques[39]. To determine drug 
content 10 tablets are triturated in the mortarand .10 
mg of powdered tablet dissolved in 10 ml of 0.1N HCL 
and after that drug sample is analysed under u.v spectro 
photometer[30,39]. 
Dissolution studies 
The dissolution test are generally performed for 
calculating the amount of drug release using USP 
dissolution apparatus.[40]. The test is performed using 
900ml of 0.1 N HCL, at 37ºC and 100 rpm[41]. A 
sample of 10 ml is withdrawn hourly and analysed 
under u.v and absorbance is measured. The sample is 
replaced by the dissolution media [42] Cumulative 
percentage is calculated using equation obtaine from 
standard curve[43-44]. 
In vivo methods 
X-ray / gamma scintigraphy 
It helps to locate dosage form in the GIT by which one 
can predict and correlate the gastric emptying time and 
the passage of dosage form in the git. The inclusion of  
a radio opaque material into solid dosage form enables 
it to be visualized by the X-ray[45]. The inclusion of a 
gamma emitting radionuclide in the formulation allows 
indirect external observation using gamma camera, the 
gamma rays emitted by radionuclide is focused on the 
camera which helps to monitor the location of the 
dosage form[46]. 
Gastroscopy 
It comprises of peroral endoscopy used with a 
fibereoptic and video system. It is used to inspect 
visually the effect of prolonged stay in stomach milieu 
on the FDDS [45][47].  
Future potentials 
• The floating drug delivery concept can be used 
in development of anti reflux formulations 
• Buoyant delivery system is beneficial in the 
treatment of gastric and duodenal ulcers. 
• Developing a controlled release of drugs which 
is used to treat Parkinson disease. 
• To explore the eradication of helicobacter pylori 
by using narrow spectrum antibiotic. 
CONCLUSION  
Under certain circumstances, the prolongation of 
gastric residence time  of a delivery system is desirable 
for achieving  a better therapeutic  benefit of the drug 
substance. For instance the drugs that show absorption 
in the proximal part of the gastrointestinal tract and the 
drugs which are degraded  or less soluble in alkaline 
pH may be benefitted by prolonging the gastric 
residence time.Prolnged gastric retention of therapeutic 
moiety offers many advantages like improved  
bioavailability , reduction of drug wastage and possible 
reduction of dose size. 
A controlled drug delivery system with prolonged 
gastric retention may have great practical importance 
for the drugs which have narrow absorption window in 
the upper small intestine. Ciprofloxacin, levodopa , 
sotalol HCL , furosemide  are examples of such drugs. 
Drugs like chlorpheniramine maleate which is locally 
used in the treatment of Helicobacter Pylori requires 
longer residence time in the stomach which can be 
achieved by designing gastroretentive dosage forms. 
Drug absorption through git is a complex procedure 
and is subjected to many variables. It is widely 
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acknowledged that extent of drug absorption is related 
to contact time of drug with intestinal mucosa . small 
intestine transit time is important parameter for drugs 
which are incompletely absorbed. Over the last two 
decades, various gastroretentive dosage forms have 
been designed to increase the gastric retention time. 
Nevertheless, there are opportunity and potential for 
the development of effective GRDDS with a improving 
bioavailability of the drugs that have absorption 
window in the proximal and mid GIT. 
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